4Q EARNINGS ROUNDUP: Alexion, Vertex and Baxter
This article was originally published in Scrip
Executive Summary
Sometimes a leadership change-up can drive a company's stock lower as investors worry about how the new chief executive will run the business, but Alexion Pharmaceuticals closed 5.8% higher at $188.05 per share on 29 January after the company said founder and CEO Leonard Bell will retire, but announced a 44% increase in annual net product sales and a 69% rise in non-GAAP earnings per share (EPS).